Issues related to development of antiepileptogenic therapies
Year: 2013
Type: article
Abstract: Several preclinical proof-of-concept studies have provided evidence for positive treatment effects on epileptogenesis. However, none of these hypothetical treatments has advanced to the clinic. The experience in other fields of neurology such as stroke, Alzheimer's disease, or amyotrophic lateral sclerosis has indicated several problems in the design of preclinical studies, which likely contribute to failures in translating the positive preclinical data to the clinic. The Working Group on "Issues related to development of antiepileptogenic therapies" of the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) has considered the possible problems that arise when moving from proof-of-concept antiepileptogenesis (AEG) studies to preclinical AEG trials, and eventually to clinical AEG trials. This article summarizes the discussions and provides recommendations on how to design a preclinical AEG monotherapy trial in adult animals. We specifically address study design, animal and model selection, number of studies needed, issues related to administration of the treatment, outcome measures, statistics, and reporting. In addition, we give recommendations for future actions to advance the preclinical AEG testing.
Source: Epilepsia
DOI: 10.1111/epi.12297
Institutions: University of Eastern Finland, Kuopio University Hospital, Hôpital Necker-Enfants Malades, Inserm, Children's Hospital Colorado, University of Colorado Anschutz, University of Utah, NYU Langone Health, Albert Einstein College of Medicine, University of Pennsylvania, UCB Pharma (Belgium), University of Virginia, University of Veterinary Medicine Hannover, Foundation, University of California, Los Angeles
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: NINDS Research Education Program for Residents and Fellows at the University of V, Identification, Treatment and Prevention of Epilepsy and Neuroprotectants, CH/BIDMC/Harvard Medical School Neurology Resident Research Education Program, Attenuating the retinal and CNS adverse effects of vigabatrin with NKCC1 inhibito, Progression of temporal lobe epilepsy, Age Related Seizure Suppression, GABA (A) Receptors in Developmental Epileptogenesis, Treatment of Status Epilepticus, The Epileptogenic Effect of Perinatal Hypoxia, Epoch Telemetry System for Long-Term Monitoring of Biopotentials, Understanding the Cognitive Impact of Early Life Epilepsy, Endogenous GABAergic Activity in the Mammalian Brain, Age related seizure suppression, Moderate-throughput screening for anti-epileptogenic drugs., Antiepileptogenic &Disease Modifying Effects of AEDs, Screening for new therapies for refractory infantile spasms, Identifying neurons and circuits critical for epileptogenesis, Targeted interneuron ablation and epileptogenesis, Ivermectin and human glycine receptor suppression of pharmacoresistant epilepsy, G6780375765, Neurosteroid Regulation of Seizures
OpenAlex ID: W1991147561